Trial Profile
Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Apr 2017 Status changed from recruiting to discontinued.
- 08 Dec 2015 Planned End Date changed from 17 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 08 Jan 2013 Planned initiation date changed from 12 Oct 2012 to NULL.